Megan Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 3 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth 1.72%
- Ebitda 1.86%
- Net Worth -106.29%
- Total Assets -0.59%
About Megan Lifesciences
Megan Lifesciences Private Limited (MLPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 February 2021 (Three years and 11 months 15 days old ). Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Travel And Hospitality Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Bhagirath Pandya, Pankajkumar Patel, Hirjibhai Patel, and One other member serve as directors at the Company.
Company Details
-
Location
Ahmedabad, Gujarat, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24299GJ2021PTC120506
-
Company No.
120506
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Feb 2021
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Megan Lifesciences?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhagirath Pandya
|
Director | 23-Feb-2021 | Current |
|
Pankajkumar Patel
|
Director | 27-Mar-2021 | Current |
|
Hirjibhai Patel
|
Director | 27-Mar-2021 | Current |
|
Palak Pandya
|
Director | 23-Feb-2021 | Current |
Financial Performance of Megan Lifesciences.
Megan Lifesciences Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a slight improvement in profitability, with a 1.72% increase in profit. The company's net worth observed a substantial decline by a decrease of 106.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Megan Lifesciences?
Unlock access to Megan Lifesciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Megan Lifesciences?
Megan Lifesciences has a workforce of 0 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Megan Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Megan Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
